Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges
Open accessThe DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Abstract
Cardiovascular diseases (CVDs) are a class of disorders affecting the heart or blood vessels. Despite progress in clinical research and therapy, CVDs still represent the leading cause of mortality and morbidity worldwide. The hallmarks of cardiac diseases include heart dysfunction and cardiomyocyte death, inflammation, fibrosis, scar tissue, hyperplasia, hypertrophy, and abnormal ventricular remodeling. The loss of cardiomyocytes is an irreversible process that leads to fibrosis and scar formation, which, in turn, induce heart failure with progressive and dramatic consequences. Both genetic and environmental factors pathologically contribute to the development of CVDs, but the precise causes that trigger cardiac diseases and their progression are still largely unknown. The lack of reliable human model systems for such diseases has hampered the unraveling of the underlying molecular mechanisms and cellular processes involved in heart diseases at their initial stage and during their progression. Over the past decade, significant scientific advances in the field of stem cell biology have literally revolutionized the study of human disease in vitro. Remarkably, the possibility to generate disease-relevant cell types from induced pluripotent stem cells (iPSCs) has developed into an unprecedented and powerful opportunity to achieve the long-standing ambition to investigate human diseases at a cellular level, uncovering their molecular mechanisms, and finally to translate bench discoveries into potential new therapeutic strategies. This review provides an update on previous and current research in the field of iPSC-driven cardiovascular disease modeling, with the aim of underlining the potential of stem-cell biology-based approaches in the elucidation of the pathophysiology of these life-threatening diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“heterogeneity of the iPSC-derived cardiomyocytes, which are mostly composed of atrial, ventricular, and nodal-like cardiomyocytes; cell survival once injected into the damaged area, and obtaining the required cell number [80], all of which may lead to cardiac arrhythmias.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“heterogeneity of the iPSC-derived cardiomyocytes, which are mostly composed of atrial, ventricular, and nodal-like cardiomyocytes; cell survival once injected into the damaged area, and obtaining the required cell number [80], all of which may lead to cardiac arrhythmias.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Stout, D. A., Basu, B., & Webster, T. J. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.04.028 · Cited by 190 · cited 1×
“These properties are retained for example by poly (vinyl alcohol) [71], polyethylene oxide [72], poly(lactic-co-glycolic acid) [73], and poly(caprolactone) [74].”
BackgroundRetractedTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926 · cited 2×
“Following their first isolation reported in 1998 [12], ESCs were predicted to provide a limitless cell source to interrogate human diseases as well as for supplying somatic cells destroyed by diseases and restoring normal function of damaged tissue.”
BackgroundMethodInduced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 2×
“Additionally, these cells have provided a robust cellular platform for the scientific community and, most importantly, have opened up the door to the development of iPSCs. iPSCs, the “artificial” counterpart of ESCs, are generated from adult somatic cells, such as skin fibroblasts, skin keratinocytes, peripheral blood…”
BackgroundEvidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130 · cited 2×
“extremely low regenerative ability after cardiac injury, despite some studies having suggested that human heart owns a certain degree of regenerative capacity [3].”
BackgroundLaflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1327 · Cited by 2,206 · cited 2×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundDisease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Doetschman, T. C., Eistetter, H., Katz, M., Schmidt, W., & Kemler, R. (1985) · Development · doi:10.1242/dev.87.1.27 · Cited by 1,962
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., Kamp, T. J., & Palecek, S. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200250109 · Cited by 1,717
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 2×
“A monolayer-based strategy allowed significant improvement of the yield of cardiac differentiation and the phenotype of derived cardiac cells exhibiting typical features of ventricular, atrial, or nodal cardiomyocytes [46].”
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · cited 1×
“iPSCs derived from healthy individuals or diseased patients carry the genome of their cell of origin and can be differentiated into any cell type, including cells not otherwise accessible, representing a powerful cell-based model system for human diseases, genetic investigations, drug screening, and personalized thera…”
BackgroundMakkar, R. R., Smith, R. R., Cheng, K., Malliaras, K., Thomson, L. E., Berman, D., Czer, L. S., Marbán, L., Mendizabal, A., Johnston, P. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60195-0 · Cited by 1,422
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., Mahoney, W. M., Van Biber, B., Cook, S. M., Palpant, N. J., et al. (2014) · Nature · doi:10.1038/nature13233 · Cited by 1,408
Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells
Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J., Palecek, S. P., Thomson, J. A., & Kamp, T. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.192237 · Cited by 1,407 · cited 1×
“Other studies have instead developed protocols to differentiate human iPSCs into specific subtypes of functional cardiac cells, such as atrial-, ventricular- [57–59], nodal-like [60] and pacemaker cells [61].”
BackgroundHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 2×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundRichard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., Benaiche, A., Isnard, R., Dubourg, O., Burban, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000066323.15244.54 · Cited by 1,279
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Polo, J. M., Liu, S., Figueroa, M. E., Kulalert, W., Eminli, S., Tan, K. Y., Apostolou, E., Stadtfeld, M., Li, Y., Shioda, T., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1667 · Cited by 1,198 · cited 1×
“As ESCs, iPSCs also have some important limitations: genomic instability, interline variability, chromosomal variations [18], genetic mutations arising during the reprogramming process, and epigenetic memory reflecting the state of the somatic cell of origin which seems to be lost upon prolonged cell passages suggesti…”
BackgroundKattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J., & Keller, G. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.008 · Cited by 1,159 · cited 1×
“Other differentiation methods require two steps: during the first step iPSCs are induced to differentiate into cardiac progenitor cells (CPCs), which in turn can be further differentiated into different cellular fates including CMs, smooth muscle cells (SMCs), and endothelial cells [48,49].”
MethodModelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Chin, M. H., Mason, M. J., Xie, W., Volinia, S., Singer, M., Peterson, C., Ambartsumyan, G., Aimiuwu, O., Richter, L., Zhang, J., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.06.008 · Cited by 1,035 · cited 1×
“Comparative gene expression analyses of human iPSCs and ESCs have indeed revealed the presence of a small number of genes that are differentially expressed between these human pluripotent stem cell lines, suggesting that iPSCs might display significant differences of molecular profiles including genomic instability an…”
BackgroundMummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., van der Heyden, M., Opthof, T., Pera, M., de la Riviere, A. B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000068356.38592.68 · Cited by 1,001 · cited 1×
“Although this protocol was successfully applied to both ESCs [33] and iPSCs [34], the CM yield is very low (less than 10%) [35].”
MethodPlaster, N. M., Tawil, R., Tristani-Firouzi, M., Canún, S., Bendahhou, S., Tsunoda, A., Donaldson, M. R., Iannaccone, S. T., Brunt, E., Barohn, R., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00342-7 · Cited by 995
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837 · cited 5×
“Some of them, such as Friedreich’s ataxia [132], Barth syndrome [25,133], fatty acid oxidation disorders, and Pompe diseases [134] have successfully been translated to iPSC-CM-based models.”
BackgroundInfluentialMarked differences in differentiation propensity among human embryonic stem cell lines
Osafune, K., Caron, L., Borowiak, M., Martinez, R. J., Fitz-Gerald, C. S., Sato, Y., Cowan, C. A., Chien, K. R., & Melton, D. A. (2008) · Nature Biotechnology · doi:10.1038/nbt1383 · Cited by 816 · cited 1×
“However, the EB-differentiation procedure, due to the presence of serum, suffers from low reproducibility and inter-line variability [37].”
BackgroundEmbryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy
Wobus, A. M., & Boheler, K. R. (2005) · Physiological Reviews · doi:10.1152/physrev.00054.2003 · Cited by 782 · cited 1×
“Human pluripotent stem cells, including ESCs and iPSCs, have the ability to differentiate into derivatives of all three primary germ layers (ectoderm, mesoderm, and endoderm) [12], under specific culture conditions, and to self-renew indefinitely through mitotic cell divisions [13].”
BackgroundMa, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., & January, C. T. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00694.2011 · Cited by 770
Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts
Shiba, Y., Fernandes, S., Zhu, W.-Z., Filice, D., Muskheli, V., Kim, J., Palpant, N. J., Gantz, J., Moyes, K. W., Reinecke, H., et al. (2012) · Nature · doi:10.1038/nature11317 · Cited by 768
Identification and classification of chromosomal aberrations in human induced pluripotent stem cells
Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J.-C., Yakir, B., Clark, A. T., Plath, K., Lowry, W. E., & Benvenisty, N. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.07.017 · Cited by 756 · cited 1×
“As ESCs, iPSCs also have some important limitations: genomic instability, interline variability, chromosomal variations [18], genetic mutations arising during the reprogramming process, and epigenetic memory reflecting the state of the somatic cell of origin which seems to be lost upon prolonged cell passages suggesti…”
BackgroundAdverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747 · cited 1×
“The latest developments at the juncture of cardiology, oncology, and hematology have been recently widely discussed [83].”
BackgroundBurridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742 · cited 1×
“CMs treated with doxorubicin showed decreased cell viability and alterations in mitochondrial function and calcium handling, demonstrating that patients with breast cancer are more prone to be affected by doxorubicin-induced cardiotoxicity [93].”
BackgroundStructural and Functional Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Lundy, S. D., Zhu, W.-Z., Regnier, M., & Laflamme, M. A. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0490 · Cited by 738 · cited 1×
“A long culture period (80–120 days) results in multinucleated iPSC-CMs exhibiting mature sarcomeres and increased electrophysiological properties compared to 20–40-day-old CMs [63].”
BackgroundEwer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726 · cited 1×
“Another chemotherapeutic agent known for its cardiotoxicity is trastuzumab [96]; by using iPSC-CMs, researchers identified mitochondrial and energy metabolism dysfunctions as mechanisms responsible for trastuzumab-driven impairment of myocardium contraction [97].”
BackgroundPatient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690
Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome
Yazawa, M., Hsueh, B., Jia, X., Pasca, A. M., Bernstein, J. A., Hallmayer, J., & Dolmetsch, R. E. (2011) · Nature · doi:10.1038/nature09855 · Cited by 677
Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons
Wainger, B. J., Kiskinis, E., Mellin, C., Wiskow, O., Han, S. S. W., Sandoe, J., Perez, N. P., Williams, L. A., Lee, S., Boulting, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.019 · Cited by 662 · cited 1×
“For example, thanks to iPSC-based screening, it was possible to identify a new application for ezogabine, an anti-epileptic drug, in amyotrophic lateral sclerosis (ALS) treatment [85] and to highlight the beneficial effects of MAP4K4 gene silencing on an iPSCs-CMs model of ischemic injury [86].”
BackgroundGoldenberg, I., & Moss, A. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.068 · Cited by 651
Gellens, M. E., George, A. L., Chen, L. Q., Chahine, M., Horn, R., Barchi, R. L., & Kallen, R. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.554 · Cited by 628
Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy
Gerull, B., Gramlich, M., Atherton, J., McNabb, M., Trombitás, K., Sasse-Klaassen, S., Seidman, J. G., Seidman, C., Granzier, H., Labeit, S., et al. (2002) · Nature Genetics · doi:10.1038/ng815 · Cited by 616
A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling
Zhao, Y., Rafatian, N., Feric, N. T., Cox, B. J., Aschar-Sobbi, R., Wang, E. Y., Aggarwal, P., Zhang, B., Conant, G., Ronaldson-Bouchard, K., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.042 · Cited by 610
Chaperone-Assisted Selective Autophagy Is Essential for Muscle Maintenance
Arndt, V., Dick, N., Tawo, R., Dreiseidler, M., Wenzel, D., Hesse, M., Fürst, D. O., Saftig, P., Saint, R., Fleischmann, B. K., et al. (2010) · Current Biology · doi:10.1016/j.cub.2009.11.022 · Cited by 574
Caspi, O., Huber, I., Kehat, I., Habib, M., Arbel, G., Gepstein, A., Yankelson, L., Aronson, D., Beyar, R., & Gepstein, L. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.054 · Cited by 573
Khorshidi, S., Solouk, A., Mirzadeh, H., Mazinani, S., Lagaron, J. M., Sharifi, S., & Ramakrishna, S. (2016) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1978 · Cited by 546 · cited 1×
“These properties are retained for example by poly (vinyl alcohol) [71], polyethylene oxide [72], poly(lactic-co-glycolic acid) [73], and poly(caprolactone) [74].”
BackgroundDubois, N. C., Craft, A. M., Sharma, P., Elliott, D. A., Stanley, E. G., Elefanty, A. G., Gramolini, A., & Keller, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.2005 · Cited by 544
Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs
Kim, C., Wong, J., Wen, J., Wang, S., Wang, C., Spiering, S., Kan, N. G., Forcales, S., Puri, P. L., Leone, T. C., et al. (2013) · Nature · doi:10.1038/nature11799 · Cited by 530
Kawamura, M., Miyagawa, S., Miki, K., Saito, A., Fukushima, S., Higuchi, T., Kawamura, T., Kuratani, T., Daimon, T., Shimizu, T., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.084343 · Cited by 495
Cardiomyocyte death: mechanisms and translational implications
Chiong, M., Wang, Z. V., Pedrozo, Z., Cao, D. J., Troncoso, R., Ibacache, M., Criollo, A., Nemchenko, A., Hill, J. A., & Lavandero, S. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.130 · Cited by 491 · cited 1×
“Many cardiac disorders, such as heart failure (HF), ischemic/reperfusion (I/R) damage, and myocardial infarction (MI), are characterized by massive cardiac myocytes death [2].”
BackgroundA Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476 · cited 5×
“Before the advent of iPSC technology, the severity of CVDs together with the lack of efficient treatments rather than transplantation pushed researchers to develop model systems of cardiac diseases comprising animal models for in vivo studies, in vitro cellular models based on the use of stem cells, primary cells, and…”
BackgroundInfluentialRuan, J.-L., Tulloch, N. L., Razumova, M. V., Saiget, M., Muskheli, V., Pabon, L., Reinecke, H., Regnier, M., & Murry, C. E. (2016) · Circulation · doi:10.1161/circulationaha.114.014998 · Cited by 467 · cited 1×
“Other methods aimed to improve CM maturation include addition of T3 hormone [65] or dexamethasone [66] in culture medium and stressing CMs with mechanical and electrical stimuli [67].”
MethodZhang, J., Klos, M., Wilson, G. F., Herman, A. M., Lian, X., Raval, K. K., Barron, M. R., Hou, L., Soerens, A. G., Yu, J., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.273144 · Cited by 445 · cited 1×
“This method relies on the pivotal role that the extracellular matrix plays in the differentiation process leading to high CM purity and yield [47].”
MethodYang, X., Rodriguez, M., Pabon, L., Fischer, K. A., Reinecke, H., Regnier, M., Sniadecki, N. J., Ruohola-Baker, H., & Murry, C. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.04.005 · Cited by 431 · cited 1×
“Other methods aimed to improve CM maturation include addition of T3 hormone [65] or dexamethasone [66] in culture medium and stressing CMs with mechanical and electrical stimuli [67].”
MethodNKX2-5eGFP/w hESCs for isolation of human cardiac progenitors and cardiomyocytes
Elliott, D. A., Braam, S. R., Koutsis, K., Ng, E. S., Jenny, R., Lagerqvist, E. L., Biben, C., Hatzistavrou, T., Hirst, C. E., Yu, Q. C., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1740 · Cited by 426
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404 · cited 1×
“The in vitro high-throughput screening performed on iPSCs-CMs derived from healthy individuals and oncologic patients allowed the identification of two TKIs against the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors as a mechanism for induced cardiotoxicity [95].”
Backgroundvan Laake, L. W., Passier, R., Monshouwer-Kloots, J., Verkleij, A. J., Lips, D. J., Freund, C., den Ouden, K., Ward-van Oostwaard, D., Korving, J., Tertoolen, L. G., et al. (2007) · Stem Cell Research · doi:10.1016/j.scr.2007.06.001 · Cited by 399
Valina, C., Pinkernell, K., Song, Y.-H., Bai, X., Sadat, S., Campeau, R. J., Le Jemtel, T. H., & Alt, E. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm426 · Cited by 390 · cited 1×
“Among the different stem cells available for potential application in cardiac regenerative medicine there are skeletal myoblasts [102], bone-marrow derived cells [103], endothelial stem cells [104], mesenchymal stem cells [105], adipose-derived stem cells [106], cardiac stem cells [107], and pluripotent stem cells [10…”
BackgroundMatsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389
Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants
Crotti, L., Johnson, C. N., Graf, E., De Ferrari, G. M., Cuneo, B. F., Ovadia, M., Papagiannis, J., Feldkamp, M. D., Rathi, S. G., Kunic, J. D., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001216 · Cited by 386
Parikh, S. S., Blackwell, D. J., Gomez-Hurtado, N., Frisk, M., Wang, L., Kim, K., Dahl, C. P., Fiane, A., Tønnessen, T., Kryshtal, D. O., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311920 · Cited by 376 · cited 1×
“Other methods aimed to improve CM maturation include addition of T3 hormone [65] or dexamethasone [66] in culture medium and stressing CMs with mechanical and electrical stimuli [67].”
MethodGuha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368 · cited 1×
“Nonetheless, iPSCs hold remarkable advantages over mutated ESCs: (1) the strategy of somatic cell reprogramming provides an unlimited, easily accessible, pluripotent cell source; (2) the in vitro derivation of iPSCs eliminates the ethical issue linked to the destruction of human embryos; (3) iPSCs retain the same gene…”
BackgroundThree-dimensional cell culture systems as an in vitro platform for cancer and stem cell modeling
Chaicharoenaudomrung, N., Kunhorm, P., & Noisa, P. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i12.1065 · Cited by 360
Norton, N., Li, D., Rieder, M. J., Siegfried, J. D., Rampersaud, E., Züchner, S., Mangos, S., Gonzalez-Quintana, J., Wang, L., McGee, S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.01.016 · Cited by 358
Swan, H., Piippo, K., Viitasalo, M., Heikkilä, P., Paavonen, T., Kainulainen, K., Kere, J., Keto, P., Kontula, K., & Toivonen, L. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00461-1 · Cited by 348
Jung, C. B., Moretti, A., Mederos y Schnitzler, M., Iop, L., Storch, U., Bellin, M., Dorn, T., Ruppenthal, S., Pfeiffer, S., Goedel, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100194 · Cited by 327
Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Muchtar, E., Blauwet, L. A., & Gertz, M. A. (2017) · Circulation Research · doi:10.1161/circresaha.117.310982 · Cited by 327
Increased Cardiomyocyte Differentiation from Human Embryonic Stem Cells in Serum‐Free Cultures
Passier, R., Oostwaard, D. W., Snapper, J., Kloots, J., Hassink, R. J., Kuijk, E., Roelen, B., de la Riviere, A. B., & Mummery, C. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0184 · Cited by 324 · cited 1×
“Although this protocol was successfully applied to both ESCs [33] and iPSCs [34], the CM yield is very low (less than 10%) [35].”
MethodCRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Mogensen, J., Kubo, T., Duque, M., Uribe, W., Shaw, A., Murphy, R. T., Gimeno, J. R., Elliot, P. M., & McKenna, W. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16336 · Cited by 313
Mogensen, J., Kubo, T., Duque, M., Uribe, W., Shaw, A., Murphy, R., Gimeno, J. R., Elliott, P., & McKenna, W. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316336 · Cited by 302
Uosaki, H., Fukushima, H., Takeuchi, A., Matsuoka, S., Nakatsuji, N., Yamanaka, S., & Yamashita, J. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023657 · Cited by 298
Cyganek, L., Tiburcy, M., Sekeres, K., Gerstenberg, K., Bohnenberger, H., Lenz, C., Henze, S., Stauske, M., Salinas, G., Zimmermann, W.-H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99941 · Cited by 297
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
Thiene, G., Corrado, D., & Basso, C. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-45 · Cited by 283
Using the mouse to model human disease: increasing validity and reproducibility
Justice, M. J., & Dhillon, P. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024547 · Cited by 281 · cited 1×
“Thus, although animal models have offered important contributions in understanding human biology and disease, they do not fully mirror the complexity of diseases as they are present in human systems and fail in the intent to translate the results of mice research to humans [4].”
BackgroundThe Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277
Paige, S. L., Osugi, T., Afanasiev, O. K., Pabon, L., Reinecke, H., & Murry, C. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011134 · Cited by 273
Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells
Weinberger, F., Breckwoldt, K., Pecha, S., Kelly, A., Geertz, B., Starbatty, J., Yorgan, T., Cheng, K.-H., Lessmann, K., Stolen, T., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8781 · Cited by 272
Scalable expansion of human pluripotent stem cells in suspension culture
Zweigerdt, R., Olmer, R., Singh, H., Haverich, A., & Martin, U. (2011) · Nature Protocols · doi:10.1038/nprot.2011.318 · Cited by 271 · cited 1×
“Large-scale production of CMs from iPSCs can be achieved using bioreactors that make the process scalable and reproducible via the continuous control and stabilization of culture parameters [78].”
BackgroundImmaturity of Human Stem-Cell-Derived Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem?
Veerman, C. C., Kosmidis, G., Mummery, C. L., Casini, S., Verkerk, A. O., & Bellin, M. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0533 · Cited by 265 · cited 1×
“Although there are currently available protocols providing a differentiation efficiency of up to 80% or more in terms of CM purity [46,49,52], all the so far reported strategies show major limitations such as heterogeneity and immaturity of the cardiac population [53].”
BackgroundThe inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis
Dhamoon, A. S., & Jalife, J. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2004.11.012 · Cited by 254
Moss, A. J. (2003) · JAMA · doi:10.1001/jama.289.16.2041 · Cited by 251
Mosqueira, D., Mannhardt, I., Bhagwan, J. R., Lis-Slimak, K., Katili, P., Scott, E., Hassan, M., Prondzynski, M., Harmer, S. C., Tinker, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy249 · Cited by 238
Kaski, J. P., Syrris, P., Burch, M., Tomé-Esteban, M.-T., Fenton, M., Christiansen, M., Andersen, P. S., Sebire, N., Ashworth, M., Deanfield, J. E., et al. (2008) · Heart · doi:10.1136/hrt.2007.134684 · Cited by 231
Itzhaki, I., Maizels, L., Huber, I., Gepstein, A., Arbel, G., Caspi, O., Miller, L., Belhassen, B., Nof, E., Glikson, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.066 · Cited by 223
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Paik, D. T., Chandy, M., & Wu, J. C. (2020) · Pharmacological Reviews · doi:10.1124/pr.116.013003 · Cited by 216 · cited 1×
“Even if the use of patient-specific iPSC-based platforms in drug discovery and personalized medicine is advantageous for many aspects, they are not yet completely affirmed in the pharmaceutical industry due to the time-consuming nature and high cost of iPSC production and differentiation processes [99].”
BackgroundLiang, P., Sallam, K., Wu, H., Li, Y., Itzhaki, I., Garg, P., Zhang, Y., Termglichan, V., Lan, F., Gu, M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.779 · Cited by 214
Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037357 · Cited by 200
Bellin, M., Casini, S., Davis, R. P., D'Aniello, C., Haas, J., Ward-van Oostwaard, D., Tertoolen, L. G. J., Jung, C. B., Elliott, D. A., Welling, A., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.240 · Cited by 196
Terrenoire, C., Wang, K., Chan Tung, K. W., Chung, W. K., Pass, R. H., Lu, J. T., Jean, J.-C., Omari, A., Sampson, K. J., Kotton, D. N., et al. (2013) · Journal of General Physiology · doi:10.1085/jgp.201210899 · Cited by 195
Caspi, O., Huber, I., Gepstein, A., Arbel, G., Maizels, L., Boulos, M., & Gepstein, L. (2013) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000188 · Cited by 186
Tester, D. J., & Ackerman, M. J. (2014) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-10-1-29 · Cited by 185
Disease characterization using LQTS-specific induced pluripotent stem cells
Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsuhashi, T., Ohno, Y., Tohyama, S., Okata, S., Seki, T., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs206 · Cited by 178
Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy
Brodehl, A., Ferrier, R. A., Hamilton, S. J., Greenway, S. C., Brundler, M.-A., Yu, W., Gibson, W. T., McKinnon, M. L., McGillivray, B., Alvarez, N., et al. (2016) · Human Mutation · doi:10.1002/humu.22942 · Cited by 178
Wu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., Lan, F., Churko, J. M., Sallam, K. I., Matsa, E., Sharma, A., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.04.020 · Cited by 177
Chen, V. C., Ye, J., Shukla, P., Hua, G., Chen, D., Lin, Z., Liu, J.-C., Chai, J., Gold, J., Wu, J., et al. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.08.002 · Cited by 174 · cited 1×
“The spinner flask methods allow critical variables to be tightly supervised, such as aggregate size and cytokine release, augmenting differentiation efficiency [80].”
MethodLalit, P. A., Salick, M. R., Nelson, D. O., Squirrell, J. M., Shafer, C. M., Patel, N. G., Saeed, I., Schmuck, E. G., Markandeya, Y. S., Wong, R., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2015.12.001 · Cited by 174 · cited 1×
“Moreover, it was recently demonstrated that induced CPCs can be directly generated using mouse fibroblasts, skipping the intermediate stage of iPSCs [50,51].”
BackgroundSmall mammalian animal models of heart disease.
Camacho, P., Fan, H., Liu, Z., & He, J. (2016) · PubMed Central · Cited by 174
3D Cardiac Cell Culture: A Critical Review of Current Technologies and Applications
Zuppinger, C. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00087 · Cited by 171
Left Ventricular Noncompaction: A New Form of Heart Failure
Towbin, J. A. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.06.005 · Cited by 171
Kodo, K., Ong, S.-G., Jahanbani, F., Termglinchan, V., Hirono, K., InanlooRahatloo, K., Ebert, A. D., Shukla, P., Abilez, O. J., Churko, J. M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3411 · Cited by 171 · cited 8×
“Left ventricular non-compaction (LVNC) is a rare congenital heart disease with relevant potential complications including arrhythmias, heart failure, embolic events, trabeculations in the left ventricle, and dysfunction of the left ventricle (hypertrophy or dilation) [198].”
BackgroundMethodInfluentialWang, Y., Liang, P., Lan, F., Wu, H., Lisowski, L., Gu, M., Hu, S., Kay, M. A., Urnov, F. D., Shinnawi, R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.057 · Cited by 170
Ma, D., Wei, H., Zhao, Y., Lu, J., Li, G., Sahib, N. B. E., Tan, T. H., Wong, K. Y., Shim, W., Wong, P., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.015 · Cited by 170
Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells
Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y.-W., Funes, C., Rusyn, I., Anson, B., & Cromwell, E. F. (2013) · SLAS Discovery · doi:10.1177/1087057112457590 · Cited by 170
Genetics of cardiac arrhythmias
Wilde, A. A. M., & Bezzina, C. R. (2005) · Heart · doi:10.1136/hrt.2004.046334 · Cited by 169
陈绍良, 方五旺, 钱钧, Fei, X., 刘煜昊, 单守杰, 张俊杰, 林松, 廖联明, & 赵春华 (2004) · PubMed · Cited by 165
Chen, S., Wu-wang, F., Qian, J., et al. (2004) · PubMed · Cited by 163
Limpitikul, W. B., Dick, I. E., Tester, D. J., Boczek, N. J., Limphong, P., Yang, W., Choi, M. H., Babich, J., DiSilvestre, D., Kanter, R. J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309283 · Cited by 161
Kadota, S., Pabon, L., Reinecke, H., & Murry, C. E. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.10.009 · Cited by 158 · cited 1×
“Among the methods developed to increase the maturation of iPSC-CMs, in vivo environments provided the most mature phenotype of iPSC-CMs [68,69].”
MethodMasumoto, H., Matsuo, T., Yamamizu, K., Uosaki, H., Narazaki, G., Katayama, S., Marui, A., Shimizu, T., Ikeda, T., Okano, T., et al. (2012) · Stem Cells · doi:10.1002/stem.1089 · Cited by 154
Hick, A., Wattenhofer-Donzé, M., Chintawar, S., Tropel, P., Simard, J. P., Vaucamps, N., Gall, D., Lambot, L., André, C., Reutenauer, L., et al. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010900 · Cited by 154
Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
Gramlich, M., Pane, L. S., Zhou, Q., Chen, Z., Murgia, M., Schötterl, S., Goedel, A., Metzger, K., Brade, T., Parrotta, E. I., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505047 · Cited by 150
Self-citationAsakura, K., Hayashi, S., Ojima, A., Taniguchi, T., Miyamoto, N., Nakamori, C., Nagasawa, C., Kitamura, T., Osada, T., Honda, Y., et al. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.04.002 · Cited by 147 · cited 1×
“Action potential is recorded using automated planar patch clamp platforms [87] or microelectrode arrays [88]; Ca2+ concentration is quantified using Ca2+-sensitive fluorophores [89]; cardiomyocyte contractility can be measured using muscular thin film [90] or dynamic monolayer force microscopy [91].”
MethodCao, N., He, L., Huang, J., Wang, J., Chen, Y., Chen, Z., & Yang, H. (2013) · Cell Research · doi:10.1038/cr.2013.102 · Cited by 143 · cited 2×
“Other differentiation methods require two steps: during the first step iPSCs are induced to differentiate into cardiac progenitor cells (CPCs), which in turn can be further differentiated into different cellular fates including CMs, smooth muscle cells (SMCs), and endothelial cells [48,49].”
BackgroundMethodKernik, D. C., Morotti, S., Wu, H., Garg, P., Duff, H. J., Kurokawa, J., Jalife, J., Wu, J. C., Grandi, E., & Clancy, C. E. (2019) · The Journal of Physiology · doi:10.1113/jp277724 · Cited by 141 · cited 1×
“iPSC technology integrated with genome-wide association studies (GWAS), next generation DNA and RNA sequencing (NGS), and chemical libraries, represents a powerful platform for cell-based screening and validation of novel therapeutic compounds and/or new targets predicted by in silico analyses [84], or for the screeni…”
BackgroundGenome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant
Garg, P., Oikonomopoulos, A., Chen, H., Li, Y., Lam, C. K., Sallam, K., Perez, M., Lux, R. L., Sanguinetti, M. C., & Wu, J. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.041 · Cited by 140
Hishiya, A., Kitazawa, T., & Takayama, S. (2010) · Circulation Research · doi:10.1161/circresaha.110.225649 · Cited by 140
Fong, A. H., Romero-López, M., Heylman, C. M., Keating, M., Tran, D., Sobrino, A., Tran, A. Q., Pham, H. H., Fimbres, C., Gershon, P. D., et al. (2016) · Tissue Engineering Part A · doi:10.1089/ten.tea.2016.0027 · Cited by 140 · cited 1×
“CMs cultured on 3D structures show an enhanced calcium signaling respect to monolayer culture [75]; however, it is mandatory to combine this method with electrical and physiological stimulation to obtain cardiac cells with a complete degree of maturity [76].”
MethodPickering, S. J., Minger, S. L., Patel, M., Taylor, H., Black, C., Burns, C. J., Ekonomou, A., & Braude, P. (2005) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61801-9 · Cited by 139 · cited 1×
“However, although very attractive, ESCs have some important limitations: only common, monogenic conditions can be captured using disease-specific ESCs derived from diseased embryos diagnosed via preimplantation screening [14]; ESCs are not genetically matched to the patients, thus, they need to undergo methods involvi…”
BackgroundUse of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity
Sharma, A., McKeithan, W. L., Serrano, R., Kitani, T., Burridge, P. W., del Álamo, J. C., Mercola, M., & Wu, J. C. (2018) · Nature Protocols · doi:10.1038/s41596-018-0076-8 · Cited by 139 · cited 1×
“Preclinical drug screenings on iPSC-derived CMs offers the opportunity to promptly discover the cardiovascular toxic effect of specific drugs [92].”
BackgroundKujala, K., Paavola, J., Lahti, A., Larsson, K., Pekkanen-Mattila, M., Viitasalo, M., Lahtinen, A. M., Toivonen, L., Kontula, K., Swan, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044660 · Cited by 136
Mehta, A., Ramachandra, C. J. A., Singh, P., Chitre, A., Lua, C. H., Mura, M., Crotti, L., Wong, P., Schwartz, P. J., Gnecchi, M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx394 · Cited by 133 · cited 1×
“The treatment of CMs with the channel modulator lumacaftor led to a recovery of the pathological phenotype in CMs with Class 2 mutations but not in those affected by Class 1 mutations, showing the importance of genetic background in the pharmacological response [98].”
Napolitano, C., Priori, S. G., & Schwartz, P. J. (1994) · Drugs · doi:10.2165/00003495-199447010-00004 · Cited by 132
‘Reprogrammed’ stem cells approved to mend human hearts for the first time
Cyranoski, D. (2018) · Nature · doi:10.1038/d41586-018-05278-8 · Cited by 132
Tambara, K., Sakakibara, Y., Sakaguchi, G., Lu, F., Premaratne, G. U., Lin, X., Nishimura, K., & Komeda, M. (2003) · Circulation · doi:10.1161/01.cir.0000087430.17543.b8 · Cited by 130 · cited 1×
“Among the different stem cells available for potential application in cardiac regenerative medicine there are skeletal myoblasts [102], bone-marrow derived cells [103], endothelial stem cells [104], mesenchymal stem cells [105], adipose-derived stem cells [106], cardiac stem cells [107], and pluripotent stem cells [10…”
BackgroundHigh prevalence of genetic variants previously associated with LQT syndrome in new exome data
Refsgaard, L., Holst, A. G., Sadjadieh, G., Haunsø, S., Nielsen, J. B., & OLESEN, M. S. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.23 · Cited by 128
Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts
Zhang, Y., Cao, N., Huang, Y., Spencer, C. I., Fu, J.-D., Yu, C., Liu, K., Nie, B., Xu, T., Li, K., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.001 · Cited by 128 · cited 1×
“Moreover, it was recently demonstrated that induced CPCs can be directly generated using mouse fibroblasts, skipping the intermediate stage of iPSCs [50,51].”
BackgroundNotch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity
Abad, M., Hashimoto, H., Zhou, H., Morales, M. G., Chen, B., Bassel‐Duby, R., & Olson, E. N. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.025 · Cited by 127 · cited 1×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundRocchetti, M., Sala, L., Dreizehnter, L., Crotti, L., Sinnecker, D., Mura, M., Pane, L. S., Altomare, C., Torre, E., Mostacciuolo, G., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx006 · Cited by 126
Archer, C. R., Sargeant, R., Basak, J., Pilling, J., Barnes, J. R., & Pointon, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28393-y · Cited by 126
The winding road to regenerating the human heart
Gerbin, K. A., & Murry, C. E. (2015) · Cardiovascular Pathology · doi:10.1016/j.carpath.2015.02.004 · Cited by 122 · cited 1×
“The number of differentiated cells obtained using classical culture methods represents an additional shortcoming for the application of iPSCs in cell therapy, given that up to one billion CMs need to be transplanted within the infarcted myocardium to replace damaged tissue [77].”
BackgroundDevelopment of 3D PVA scaffolds for cardiac tissue engineering and cell screening applications
Dattola, E., Parrotta, E. I., Scalise, S., Perozziello, G., Limongi, T., Candeloro, P., Coluccio, M. L., Maletta, C., Bruno, L., Angelis, M. T. D., et al. (2019) · RSC Advances · doi:10.1039/c8ra08187e · Cited by 122 · cited 1×
“These properties are retained for example by poly (vinyl alcohol) [71], polyethylene oxide [72], poly(lactic-co-glycolic acid) [73], and poly(caprolactone) [74].”
BackgroundSelf-citationCardiac Induction of Embryonic Stem Cells by a Small Molecule Inhibitor of Wnt/β-Catenin Signaling
Wang, H., Hao, J., & Hong, C. C. (2011) · ACS Chemical Biology · doi:10.1021/cb100323z · Cited by 121 · cited 1×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundA Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations
Cohn, R. L., Thakar, K., Lowe, A., Ladha, F. A., Pettinato, A. M., Romano, R., Meredith, E. K., Chen, Y.-S., Atamanuk, K., Huey, B. D., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.11.015 · Cited by 121
Spencer, C. I., Baba, S., Nakamura, K., Hua, E. A., Sears, M. A. F., Fu, C.-C., Zhang, J., Balijepalli, S., Tomoda, K., Hayashi, Y., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.06.003 · Cited by 120
The use of nanotechnology in cardiovascular disease
Chandarana, M., Curtis, A. D. M., & Hoskins, C. (2018) · Applied Nanoscience · doi:10.1007/s13204-018-0856-z · Cited by 119 · cited 1×
“Currently, nanotechnology-based approaches offer new perspectives in many fields of biomedical research, including cardiovascular research [70].”
BackgroundLin, B., Li, Y., Han, L., Kaplan, A. D., Ao, Y., Kalra, S., Bett, G. C. L., Rasmusson, R. L., Denning, C., & Yang, L. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019505 · Cited by 116
Molecular pathogenesis of long QT syndrome type 2
Smith, J. L., Anderson, C. L., Burgess, D. E., Elayi, C. S., January, C. T., & Delisle, B. P. (2016) · Journal of Arrhythmia · doi:10.1016/j.joa.2015.11.009 · Cited by 115
Tse, H., Siu, C., Zhu, S., Songyan, L., Zhang, Q., Lai, W., Kwong, Y., Nicholls, J. M., & Lau, C. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.03.008 · Cited by 114 · cited 1×
“Among the different stem cells available for potential application in cardiac regenerative medicine there are skeletal myoblasts [102], bone-marrow derived cells [103], endothelial stem cells [104], mesenchymal stem cells [105], adipose-derived stem cells [106], cardiac stem cells [107], and pluripotent stem cells [10…”
BackgroundKawamura, M., Miyagawa, S., Fukushima, S., Saito, A., Miki, K., Funakoshi, S., Yoshida, Y., Yamanaka, S., Shimizu, T., Okano, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08869-z · Cited by 112
Quality Metrics for Stem Cell-Derived Cardiac Myocytes
Sheehy, S. P., Pasqualini, F., Grosberg, A., Park, S. J., Aratyn-Schaus, Y., & Parker, K. K. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.01.015 · Cited by 110 · cited 1×
“Action potential is recorded using automated planar patch clamp platforms [87] or microelectrode arrays [88]; Ca2+ concentration is quantified using Ca2+-sensitive fluorophores [89]; cardiomyocyte contractility can be measured using muscular thin film [90] or dynamic monolayer force microscopy [91].”
Weng, Z., Kong, C.-W., Ren, L., Karakikes, I., Geng, L., He, J., Chow, M. Z. Y., Mok, C. F., Chan, H. Y. S., Webb, S. E., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0509 · Cited by 109
Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes
Machiraju, P., & Greenway, S. C. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i1.33 · Cited by 108 · cited 1×
“iPSC-CMs display a disorganized morphology, reduced contractile capacity, alteration of glycolytic metabolism, abnormal electrophysiological properties, and reduced automaticity [62].”
BackgroundLi, S., Pan, H., Tan, C., Sun, Y., Song, Y., Zhang, X., Yang, W., Wang, X., Li, D., Dai, Y., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.013 · Cited by 106
Poolman, R. A., & Brooks, G. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0808 · Cited by 105 · cited 1×
“The regenerative capability of the human heart is still a controversial question in the scientific community: for a long time it has been thought that the regeneration capability of the human cardiac tissue decreases immediately after birth and postnatal cardiac cells have been considered “terminally differentiated” c…”
BackgroundEndothelial Progenitor Cells for Cardiovascular Regeneration
Kawamoto, A., & Losordo, D. W. (2008) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.11.004 · Cited by 103 · cited 1×
“Among the different stem cells available for potential application in cardiac regenerative medicine there are skeletal myoblasts [102], bone-marrow derived cells [103], endothelial stem cells [104], mesenchymal stem cells [105], adipose-derived stem cells [106], cardiac stem cells [107], and pluripotent stem cells [10…”
BackgroundChaudhari, U., Nemade, H., Wagh, V., Gaspar, J. A., Ellis, J. K., Srinivasan, S. P., Spitkovski, D., Nguemo, F., Louisse, J., Bremer, S., et al. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1623-5 · Cited by 102 · cited 1×
“Cardiotoxicity due to repeated exposure to doxorubicin has been documented also in iPSC-CMs derived from healthy subjects [94].”
BackgroundFiedler, L. R., Chapman, K., Xie, M., Maifoshie, E., Jenkins, M., Golforoush, P. A., Bellahcene, M., Noseda, M., Faust, D., Jarvis, A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.01.013 · Cited by 102
Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing
Kostareva, A. A., Kiselev, A. M., Gudkova, A. Y., Frishman, G., Ruepp, A., Frishman, D., Smolina, N., Tarnovskaya, S. I., Nilsson, D., Zlotina, A. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163362 · Cited by 100
Electro-mechanical conditioning of human iPSC-derived cardiomyocytes for translational research
Kroll, K. T., Chabria, M., Wang, K., Häusermann, F., Schuler, F., & Polonchuk, L. (2017) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2017.07.003 · Cited by 99 · cited 1×
“CMs cultured on 3D structures show an enhanced calcium signaling respect to monolayer culture [75]; however, it is mandatory to combine this method with electrical and physiological stimulation to obtain cardiac cells with a complete degree of maturity [76].”
MethodCho, G.-S., Lee, D. I., Tampakakis, E., Murphy, S., Andersen, P., Uosaki, H., Chelko, S., Chakir, K., Hong, I., Seo, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.040 · Cited by 98 · cited 1×
“Among the methods developed to increase the maturation of iPSC-CMs, in vivo environments provided the most mature phenotype of iPSC-CMs [68,69].”
MethodMa, D., Wei, H., Lu, J., Huang, D., Liu, Z., Loh, L. J., Islam, O., Liew, R., Shim, W., & Cook, S. A. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0027-z · Cited by 96
Arai, A., Yamamoto, K., & Toyama, J. (1997) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(199711)210:3<344::aid-aja13>3.0.co;2-a · Cited by 94 · cited 1×
“During embryonic development in vivo, visceral END-2 releases factors that lead to cardiac differentiation of the nearby mesoderm [32]; this discovery was the basis of the co-culture strategy in which PSCs cultured either in the presence of END-2 cells or in END-2-conditioned medium enter cardiac fate.”
BackgroundFlow Characterization of a Spinner Flask for Induced Pluripotent Stem Cell Culture Application
Ismadi, M.-Z., Gupta, P., Fouras, A., Verma, P., Jadhav, S., Bellare, J., & Hourigan, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106493 · Cited by 93
Yang, K.-C., Breitbart, A., De Lange, W. J., Hofsteen, P., Futakuchi-Tsuchida, A., Xu, J., Schopf, C., Razumova, M. V., Jiao, A., Boucek, R., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.008 · Cited by 93
Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction
Malan, D., Zhang, M., Stallmeyer, B., Müller, J., Fleischmann, B. K., Schulze-Bahr, E., Sasse, P., & Greber, B. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0530-0 · Cited by 91
Jiang, Y., Park, P., hong, S., & Ban, K. (2018) · PubMed · doi:10.14348/molcells.2018.0143 · Cited by 90
Interplay of cell–cell contacts and RhoA/ MRTF ‐A signaling regulates cardiomyocyte identity
Dorn, T., Kornherr, J., Parrotta, E. I., Zawada, D., Ayetey, H., Santamaria, G., Iop, L., Mastantuono, E., Sinnecker, D., Goedel, A., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798133 · Cited by 88
Self-citationRemme, C. A., Scicluna, B. P., Verkerk, A. O., Amin, A. S., van Brunschot, S., Beekman, L., Deneer, V. H. M., Chevalier, C., Oyama, F., Miyazaki, H., et al. (2009) · Circulation Research · doi:10.1161/circresaha.109.194423 · Cited by 87
Banking on iPSC- Is it Doable and is it Worthwhile
Solomon, S., Pitossi, F., & Rao, M. S. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9574-4 · Cited by 86 · cited 1×
“To overcome this issue, Solomon and colleagues have proposed the establishment of a biobank containing several iPSC lines reprogrammed from healthy donors carrying different combinations of human leukocyte antigen (HLA) alleles in order to provide a shared and economic starting point from which iPSC-derived differenti…”
BackgroundNovel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy
Tucker, N. R., McLellan, M. A., Hu, D., Ye, J., Parsons, V. A., Mills, R. W., Clauß, S., Dolmatova, E. V., Shea, M. A., Milan, D. J., et al. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001780 · Cited by 84
Fatima, A., Kaifeng, S., Dittmann, S., Xu, G., Gupta, M. K., Linke, M., Zechner, U., Nguemo, F., Milting, H., Farr, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083005 · Cited by 83
Bhattacharya, S., Burridge, P. W., Kropp, E. M., Chuppa, S. L., Kwok, W.-M., Wu, J. C., Boheler, K. R., & Gundry, R. L. (2014) · Journal of Visualized Experiments · doi:10.3791/52010 · Cited by 83 · cited 1×
“Different small molecules have been tested for their ability to promote in vitro cardiac differentiation; activators (CHIR99021) and inhibitors (IWR, XAV, IWP2) of the Wnt pathway have been proved to increase cardiac differentiation [43].”
BackgroundMuscle-bone interactions during fracture healing.
Davis, K. M., Griffin, K. S., Chu, T. G., Wenke, J. C., Corona, B. T., McKinley, T. O., & Kacena, M. A. (2015) · PubMed Central · Cited by 82
Badenes, S. M., Fernandes, T. G., Cordeiro, C. S. M., Boucher, S., Kuninger, D., Vemuri, M. C., Diogo, M. M., & Cabral, J. M. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151264 · Cited by 81 · cited 1×
“The culture in the suspension of cells that are adhesion-dependent for survival and proliferation can be obtained through the use of supporting matrices known as microcarriers [81].”
BackgroundLee, Y.-K., Lau, Y., Cai, Z., Lai, W., Wong, L., Tse, H., Ng, K., & Siu, C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005677 · Cited by 81
Vascularized cardiac spheroids as novel 3D in vitro models to study cardiac fibrosis
Figtree, G. A., Bubb, K. J., Tang, O., Kizana, E., & Gentile, C. (2017) · Cells Tissues Organs · doi:10.1159/000477436 · Cited by 79
Embryonic Stem Cell Therapy of Heart Failure in Genetic Cardiomyopathy
Yamada, S., Nelson, T. J., Crespo‐Diaz, R. J., Pérez-Terzic, C. M., Liu, X., Miki, T., Seino, S., Behfar, A., & Terzic, A. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0187 · Cited by 78
Schweizer, P. A., Darche, F. F., Ullrich, N. D., Geschwill, P., Greber, B., Rivinius, R., Seyler, C., Müller-Decker, K., Draguhn, A., Utikal, J., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0681-4 · Cited by 76 · cited 1×
“Other studies have instead developed protocols to differentiate human iPSCs into specific subtypes of functional cardiac cells, such as atrial-, ventricular- [57–59], nodal-like [60] and pacemaker cells [61].”
BackgroundEbert, A., Joshi, A. U., Andorf, S., Dai, Y., Sampathkumar, S., Chen, H., Li, Y., Garg, P., Toischer, K., Hasenfuss, G. P., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.313973 · Cited by 75 · cited 1×
“This higher grade of maturity of long-term culture CMs is strictly related to mitochondrial metabolism regulation, which is necessary for energy production and increased cell contractility [64].”
BackgroundRestrictive cardiomyopathy with atrioventricular conduction block resulting from a desmin mutation
Pruszczyk, P., Kostera‐Pruszczyk, A., Shatunov, A., Goudeau, B., Dramińska, A., Takeda, K., Sambuughin, N., Vicart, P., Strelkov, S. V., Goldfarb, L. G., et al. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.05.019 · Cited by 74
Ethical Issues in Genome Editing using Crispr/Cas9 System
E, R. (2016) · Journal of Clinical Research & Bioethics · doi:10.4172/2155-9627.1000266 · Cited by 74 · cited 1×
“If on one side CRISPR-Cas9 has permitted a variety of genomes to become available, on the other side, the technology has pointed out several issues, with particular regards to the extent of its applications on all human genomes as well as germ cell line modifications, and other concerns elegantly reviewed elsewhere [2…”
BackgroundBrodehl, A., Hakimi, S. A. P., Stanasiuk, C., Ratnavadivel, S., Hendig, D., Gärtner, A., Gerull, B., Gummert, J. F., Paluszkiewicz, L., & Milting, H. (2019) · Genes · doi:10.3390/genes10110918 · Cited by 74
Kadari, A., Mekala, S. R., Wagner, N., Malan, D., Köth, J., Doll, K., Stappert, L., Eckert, D., Peitz, M., Matthes, J., et al. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9564-6 · Cited by 72 · cited 1×
“To overcome the limitations of methods based on EB formation, differentiation protocols have been developed based on cell monolayers but with the use of the same molecular factors described for EB differentiation [44,45].”
MethodPreininger, M. K., Jha, R., Maxwell, J. T., Wu, Q., Singh, M., Wang, B., Dalal, A., Mceachin, Z. T., Rossoll, W., Hales, C. M., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.026823 · Cited by 69
Modeling of LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cells
Shah, D., Virtanen, L., Prajapati, C., Kiamehr, M., Gullmets, J., West, G., Kreutzer, J., Pekkanen-Mattila, M., Heliö, T., Kallio, P., et al. (2019) · Cells · doi:10.3390/cells8060594 · Cited by 69
Chen, Y., Zeng, D., Ding, L., Li, X., Liu, X., Li, W., Wei, T., Yan, S., Xie, J.-H., Li, W., et al. (2015) · BMC Cell Biology · doi:10.1186/s12860-015-0067-3 · Cited by 66 · cited 1×
“These properties are retained for example by poly (vinyl alcohol) [71], polyethylene oxide [72], poly(lactic-co-glycolic acid) [73], and poly(caprolactone) [74].”
BackgroundRamalingam, S., Annaluru, N., Kandavelou, K., & Chandrasegaran, S. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140918101725 · Cited by 65 · cited 1×
“The main tools allowing precise genomic manipulation in wild-type and diseased iPSCs are represented by zinc-finger nucleases (ZNFs) [21], transcription-activator like effector nucleases (TALENs) [22], and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system [23]…”
MethodSasaki, K., Makiyama, T., Yoshida, Y., Wuriyanghai, Y., Kamakura, T., Nishiuchi, S., Hayano, M., Harita, T., Yamamoto, Y., Kohjitani, H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164795 · Cited by 65
van Mil, A., Balk, G. M., Neef, K., Buikema, J. W., Asselbergs, F. W., Wu, S. M., Doevendans, P. A., & Sluijter, J. P. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy208 · Cited by 65
Freund, C. M. A. H., Davis, R. P., Gkatzis, K., Oostwaard, D. W., & Mummery, C. L. (2010) · PubMed · Cited by 61
Banerjee, I., Carrion, K., Serrano, R., Dyo, J., Sasik, R., Lund, S., Willems, E., Aceves, S., Meili, R., Mercola, M., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.003 · Cited by 59 · cited 1×
“Action potential is recorded using automated planar patch clamp platforms [87] or microelectrode arrays [88]; Ca2+ concentration is quantified using Ca2+-sensitive fluorophores [89]; cardiomyocyte contractility can be measured using muscular thin film [90] or dynamic monolayer force microscopy [91].”
MethodBastakoty, D. (2016) · Cell Stem cells and Regenerative Medicine · doi:10.16966/2472-6990.111 · Cited by 59 · cited 1×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundAl‐Haque, S., Miklas, J. W., Feric, N. T., Chiu, L. L. Y., Chen, W. L. K., Simmons, C. A., & Radisic, M. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201200042 · Cited by 58
Argenziano, M., Lambers, E., Hong, L., Sridhar, A., Zhang, M., Chalazan, B., Menon, A., Savio-Galimberti, E., Wu, J. C., Rehman, J., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.04.005 · Cited by 58
Dai, Y., Amenov, A., Ignatyeva, N., Koschinski, A., Xu, H., Soong, P. L., Tiburcy, M., Linke, W. A., Zaccolo, M., Hasenfuss, G. P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56597-3 · Cited by 58
Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells
Sala, L., Gnecchi, M., & Schwartz, P. J. (2019) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2019.1.1 · Cited by 54
Huby, A.-C., Mendsaikhan, U., Takagi, K., Martherus, R., Wansapura, J. P., Gong, N., Osińska, H. E., James, J. F., Kramer, K., Saito, K., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.071 · Cited by 54
Ramalingam, S., London, V., Kandavelou, K., Cebotaru, L., Guggino, W. B., Civin, C. I., & Chandrasegaran, S. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0245 · Cited by 53
Rammos, A., Meladinis, V., Vovas, G., & Patsouras, D. (2017) · Radiology Research and Practice · doi:10.1155/2017/2874902 · Cited by 51
Bruntraeger, M., Byrne, M. L., Long, K. R., & Bassett, A. R. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_11 · Cited by 50 · cited 1×
“The main tools allowing precise genomic manipulation in wild-type and diseased iPSCs are represented by zinc-finger nucleases (ZNFs) [21], transcription-activator like effector nucleases (TALENs) [22], and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system [23]…”
MethodLaco, F., Lam, A. T., Woo, T. L., Tong, G. J.-L., Ho, V., Soong, P. L., Grishina, E., Lin, K., Reuveny, S., & Oh, S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01618-6 · Cited by 50 · cited 2×
“Laco et al. (2020) developed a microcarrier culture system in a tank bioreactor that allowed scalable iPSC expansion and CM differentiation and purification, reaching a yield of ~40 CMs per iPSC seeded after 22 days in culture [82].”
BackgroundMethodde la Roche, J., Angsutararux, P., Kempf, H., Janan, M., Bolesani, E., Thiemann, S., Wojciechowski, D., Coffee, M., Franke, A., Schwanke, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47632-4 · Cited by 49
Toward the realization of cardiac regenerative medicine using pluripotent stem cells
Kishino, Y., Fujita, J., Tohyama, S., Okada, M., Tanosaki, S., Someya, S., & Fukuda, K. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-019-0110-4 · Cited by 48
Wu, W., Lu, C., Wang, Y., Liu, F., Chen, W., Liu, Y., Han, Y., Cao, J., Zhang, S., & Zhang, X. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001879 · Cited by 47
Sato, Y., Kobayashi, H., Higuchi, T., Shimada, Y., Era, T., Kimura, S., Eto, Y., Ida, H., & Ohashi, T. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.23 · Cited by 43
McDermott-Roe, C., Lv, W., Maximova, T., Wada, S., Bukowy, J., Marquez, M., Lai, S., Shehu, A., Benjamin, I., Geurts, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128799 · Cited by 43 · cited 18×
“Dilated cardiomyopathy (DCM) is a group of heterogenous non-ischemic heart muscle diseases that associate with functional and structural abnormalities.”
BackgroundInfluentialCatecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy
Roston, T. M., Petegem, F. V., & Sanatani, S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000360 · Cited by 42
Parrotta, E. I., Angelis, M. T. D., Scalise, S., Candeloro, P., Santamaria, G., Paonessa, M., Coluccio, M. L., Perozziello, G., Vitis, S. D., Sgura, A., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0720-1 · Cited by 41
Self-citationMolecular Analysis of LEFTY-Expressing Cells in Early Human Embryoid Bodies
Dvash, T., Sharon, N., Yanuka, O., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0179 · Cited by 41 · cited 1×
“These features make them very promising in a variety of basic research and clinical applications such as developmental biology [5], drug screening, disease modelling, and regenerative medicine.”
Background
Cited by
Abdollahiyan, P., Oroojalian, F., & Mokhtarzadeh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.036 · Cited by 99
Wen, Z.-J., Wang, Z., & Zhang, Y. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.157443 · Cited by 102
Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations
Park, G., Rim, Y. A., Sohn, Y., Nam, Y., & Ju, J. H. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10723-5 · Cited by 92
“…that leads to scar formation and ultimately heart function failure, there are existing studies that explore iPSCs for novel therapeutic cures [ 84]. iPSC-derived progenitors such as human HCN4 + and human ESC derived ROR2 + , CD13 + , KDR + , PDGFRα + cells later generate cardiomyocytes [ 47].”
BackgroundUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 72
“stem cells with specific disease phenotypes, and they are usually not genetically matched with patients for transplantation.(307) The breakthrough”
BackgroundInfluential
Metadata
- Authors
- Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G.
- Affiliations
- Magna Graecia University (IT)
- Corresponding author
- Parrotta, Elvira Immacolata
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-19
- Volume
- 21
- Issue
- 12
- Pages
- 4354
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352327
- OpenAlex
- W3036591244
- Cited by
- 88
- References
- 212
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 15 · 2022: 12 · 2021: 17 · 2020: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- induced pluripotent stem cells, iPSC-derived cardiomyocytes, cardiovascular disease modeling, cardiomyocyte death, myocardial fibrosis, heart failure, ventricular remodeling, cardiomyocyte hypertrophy, cardiomyocyte hyperplasia, cardiac inflammation, disease pathophysiology, stem cell therapy
- MeSH terms
- Cell Differentiation, Heart Diseases, Humans, Models, Biological, Signal Transduction, Disease Progression, Myocytes, Cardiac, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.